{"preliminary_commentary":{"by_channel":{"x_thread":26,"youtube":13,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06413498\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"iMMagine-3","nct_id":"NCT06413498","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=immagine-3-nct06413498. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"iMMagine-3","arms":[{"description":"Participants with RRMM will receive lymphodepletion chemotherapy with cyclophosphamide and fludarabine for 3 days followed by single dose of anitocabtagene autoleucel chimeric antigen receptor positive (CAR+) on Day 1.","label":"Anitocabtagene Autoleucel","type":"EXPERIMENTAL"},{"description":"Participants will receive the investigator's choice of one of the following therapies:\n\n* pomalidomide, bortezomib, and dexamethasone (PVd) (21-day cycles)\n* daratumumab, pomalidomide, and dexamethasone (DPd) (28-day cycles)\n* carfilzomib, daratumumab, and dexamethasone (KDd) (28-day cycles)\n* carfilzomib and dexamethasone (Kd) (28-day cycles)","label":"Standard of Care Therapy (SOCT)","type":"ACTIVE_COMPARATOR"}],"collaborators":["Arcellx, Inc."],"completion_date":{"date":"2031-07","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":452,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Anitocabtagene Autoleucel","otherNames":["CART-ddBCMA"],"type":"DRUG"},{"name":"Cyclophosphamide","otherNames":[],"type":"DRUG"},{"name":"Fludarabine","otherNames":[],"type":"DRUG"},{"name":"Pomalidomide","otherNames":[],"type":"DRUG"},{"name":"Bortezomib","otherNames":[],"type":"DRUG"},{"name":"Dexamethasone","otherNames":[],"type":"DRUG"},{"name":"Daratumumab","otherNames":[],"type":"DRUG"},{"name":"Carfilzomib","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-29","lead_sponsor":"Kite, A Gilead Company","official_title":"A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-07","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS)","timeFrame":"Up to 4 years"},{"measure":"Minimal Residual Disease (MRD) Complete Response (CR) Rate at 9 Months","timeFrame":"Up to 9 months"}],"references":[],"start_date":{"date":"2024-08-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT06413498"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/immagine-3-nct06413498"}